NASDAQ:BIOC Biocept Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biocept Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.49 +0.11 (+2.51 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$4.36Now: $4.49▼$4.5650-Day Range$0.53MA: $6.80▼$11.4052-Week Range$2.11Now: $4.49▼$13.00Volume329,799 shsAverage Volume2.01 million shsMarket Capitalization$60.13 millionP/E RatioN/ADividend YieldN/ABeta0.64 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingBiocept has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Biocept has a forecasted upside of 345.4% from its current price of $4.49.Amount of Analyst CoverageBiocept has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesBiocept has received 342 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBiocept has received 346 “underperform” votes. (Add your “underperform” vote.)Community SentimentBiocept has received 50.29% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote “Outperform” if you believe BIOC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBiocept does not currently pay a dividend.Dividend GrowthBiocept does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biocept insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.40% of the stock of Biocept is held by insiders.Percentage Held by InstitutionsOnly 10.24% of the stock of Biocept is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Biocept are expected to decrease in the coming year, from ($0.42) to ($1.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biocept is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biocept is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiocept has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.20 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOC Previous Symbol CUSIPN/A CIK1044378 Webwww.biocept.com Phone858-320-8200Debt Debt-to-Equity Ratio0.05 Current Ratio5.16 Quick Ratio4.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.53 million Price / Sales10.87 Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book1.91Profitability EPS (Most Recent Fiscal Year)($12.20) Net Income$-25,140,000.00 Net Margins-462.43% Return on Equity-142.34% Return on Assets-101.38%Miscellaneous Employees95 Outstanding Shares13,393,000Market Cap$60.13 million Next Earnings Date11/11/2020 (Estimated) OptionableOptionable $4.49 +0.11 (+2.51 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BIOC News and Ratings via Email Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter. Biocept (NASDAQ:BIOC) Frequently Asked Questions How has Biocept's stock price been impacted by COVID-19? Biocept's stock was trading at $3.7690 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BIOC shares have increased by 19.1% and is now trading at $4.49. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Biocept? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biocept. When is Biocept's next earnings date? Biocept is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020. View our earnings forecast for Biocept. How were Biocept's earnings last quarter? Biocept Inc (NASDAQ:BIOC) posted its earnings results on Wednesday, August, 12th. The medical research company reported ($0.50) EPS for the quarter, hitting analysts' consensus estimates of ($0.50). The medical research company had revenue of $0.92 million for the quarter, compared to the consensus estimate of $1.30 million. Biocept had a negative return on equity of 142.34% and a negative net margin of 462.43%. View Biocept's earnings history. When did Biocept's stock split? How did Biocept's stock split work? Biocept shares reverse split on the morning of Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for BIOC? 2 analysts have issued 1-year price targets for Biocept's shares. Their forecasts range from $20.00 to $20.00. On average, they expect Biocept's stock price to reach $20.00 in the next year. This suggests a possible upside of 345.4% from the stock's current price. View analysts' price targets for Biocept. Are investors shorting Biocept? Biocept saw a decline in short interest in August. As of August 31st, there was short interest totaling 3,180,000 shares, a decline of 28.1% from the August 15th total of 4,420,000 shares. Based on an average trading volume of 2,630,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 23.8% of the shares of the stock are sold short. View Biocept's Short Interest. Who are some of Biocept's key competitors? Some companies that are related to Biocept include Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Miragen Therapeutics (MGEN), OpGen (OPGN), Psychemedics (PMD), Avant Diagnostics (AVDX), PotNetwork (POTN), American Shared Hospital Services (AMS), Cancer Genetics (CGIX), CBA Florida (CBAI), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC). View all competitors. What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include Ibio (IBIO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Acasti Pharma (ACST), Inovio Pharmaceuticals (INO) and Walmart (WMT). Who are Biocept's key executives? Biocept's management team includes the following people: Mr. Michael W. Nall, CEO, Pres & Director (Age 56)Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)Dr. Soon Kap Hahn Ph.D., FounderMr. Pavel Tsinberg, Director of Technology Devel. What is Biocept's stock symbol? Biocept trades on the NASDAQ under the ticker symbol "BIOC." Who are Biocept's major shareholders? Biocept's stock is owned by a number of institutional and retail investors. Top institutional investors include Hudson Bay Capital Management LP (0.03%). View institutional ownership trends for Biocept. Which major investors are buying Biocept stock? BIOC stock was purchased by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP. View insider buying and selling activity for Biocept. How do I buy shares of Biocept? Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Biocept's stock price today? One share of BIOC stock can currently be purchased for approximately $4.49. How big of a company is Biocept? Biocept has a market capitalization of $60.13 million and generates $5.53 million in revenue each year. The medical research company earns $-25,140,000.00 in net income (profit) each year or ($12.20) on an earnings per share basis. Biocept employs 95 workers across the globe. What is Biocept's official website? The official website for Biocept is www.biocept.com. How can I contact Biocept? Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
